- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
June 17th, 2007
Tempo Hurries To Target Nanoparticle Combo Drugs
Tempo Pharmaceuticals Inc. isn't wasting any time. Since its founding in late 2006, the Cambridge, Mass.-based company has raised Seed and Series A financings, licensed core technology, hired 15 employees, started partnership discussions and begun the process of translating its platform into a product fit for clinical trials.
Yet founder and CEO Alan Crane said the name Tempo refers not to the company's frenetic pace, but to the "temporal release" of multiple drugs from its Nanocell platform technology.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016